Sep 04 2026
/
Evidence Without Context: Why Advanced Analytics Still Miss Commercial Reality
Advanced analytics has transformed how life sciences teams generate evidence. We can analyze massive datasets, model future markets, and simulate treatment pathways with remarkable precision. Yet despite this sophistication, many commercial and market access decisions still feel uncertain not because teams lack data, but because the data often lacks context.
It’s increasingly common to see forecasts that look robust on paper but fall apart in real-world execution. Market sizing feels inflated. Uptake curves feel optimistic. Payers push back, sales teams hesitate, and leadership asks the same question: Why doesn’t this reflect what we’re actually seeing?
The problem usually isn’t analytical rigor. It’s the gap between evidence and commercial reality.
When Analytics Optimizes for Precision, Not Practice
Most analytics frameworks are built to be technically correct. They prioritize clean assumptions, logical treatment flows, and measurable endpoints. But real-world healthcare rarely behaves that neatly.
Physicians don’t prescribe purely by guideline. Patients don’t move smoothly through lines of therapy. Access decisions aren’t driven by data alone, they’re shaped by habit, workflow pressure, site-of-care economics, reimbursement friction, and regional variation.
When these factors are left out, even a well-built model becomes fragile.
It can look impressive and still fail to answer the question leadership actually cares about: Will this change what physicians prescribe, what payers reimburse, or how patients move through care?
Why More Data Doesn’t Automatically Mean Better Insight
Real-world data is often treated as the missing piece. But adding more data doesn’t solve the problem if the interpretation stays shallow.
Claims data can show switching, but not the hesitation behind it. EHR data can show discontinuation, but not the burden that drove it. Large datasets reveal patterns while hiding the operational friction underneath them.
Without commercial framing, analytics stays descriptive instead of decision-ready. Teams end up equipped to explain what happened, not to act on what will happen next.
A practical example. In one recent engagement, a client came to us with a forecast for a specialty therapy that projected steady, near-linear uptake over three years, built on a standard patient-flow model with reasonable-looking assumptions about diagnosis rates and switch propensity. The model was sound. It was also wrong in a specific, fixable way: it treated all eligible sites of care as equally likely to adopt early, when in practice, uptake for that class had historically concentrated in a small number of high-volume academic centers for the first 12-18 months before spreading to community settings. Once we rebuilt the curve around that center-concentration pattern, using site-level treatment data rather than national averages, the early-year forecast dropped by roughly a third, but the model became something the commercial and access teams could actually plan against: which accounts to prioritize first, when field force expansion made sense, and where payer friction would show up earliest. The data didn’t change. The context did.
The Questions That Often Go Unanswered
Commercial leaders aren’t just looking for numbers. They’re trying to understand feasibility:
- Which eligible patients will realistically get treated, not just which patients qualify on paper?
- Where does access actually break down: coverage, affordability, or physician confidence?
- Which competitors are truly at risk in practice, not just in theory?
- What happens to uptake when administrative burden increases, even slightly?
These questions live at the intersection of data, behavior, and systems, not in a spreadsheet alone.
Forecasts Fail When Human Behavior Is Ignored
Forecasting is where the context gap shows up most clearly. Models often assume rational switching and steady adoption. Reality looks different: cautious prescribers, delayed uptake, concentration in a few centers, and the persistence of older therapies despite objectively better options.
When human behavior is abstracted away, forecasts become confident but wrong and commercial teams are left explaining variance instead of acting on insight.
Context Turns Evidence into Intelligence
The answer isn’t simpler analytics or more complex models. It’s changing the role evidence plays.
Effective analytics starts with the decision, not the dataset. It tests assumptions against real-world constraints: site-of-care patterns, payer policy nuance, regional prescribing behavior. It accepts uncertainty instead of hiding it behind false precision.
This is the gap we spend most of our time closing at Thelansis. Our epidemiological models and market forecasts are built to be cross-validated against real registry and claims data from the start, and stress-tested against the operational realities, such as site concentration, access friction, and prescriber behavior that determine whether a number holds up outside the deck. The goal isn’t a more elaborate model; it’s a forecast your commercial and access teams can actually act on.
In a world where data is abundant, context is what creates advantage. Because evidence without context isn’t insight, it’s noise.